Cite

HARVARD Citation

    Germain, V. et al. (2020). Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect. Annals of the rheumatic diseases. 79 (1), p. e11. [Online]. 
  
Back to record